Trial Outcomes & Findings for A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer (NCT NCT04148937)

Last Updated: 2024-04-05

Results Overview

A DLT is defined as an adverse event that is likely related to the study medication or combination, and fulfils any one of the following criteria, graded according to the NCI-CTCAE (National Cancer Institute-Common Terminology Criteria for Adverse Events) version 5.0: * Grade 3 thrombocytopenia associated with clinically significant bleeding and requiring platelet transfusion or Grade 4 thrombocytopenia of any duration. * Grade ≥3 febrile neutropenia * Grade ≥3 anemia requiring a blood transfusion * Other Grade ≥4 toxicities, excluding few nonhematologic Toxicities * Any other significant toxicity deemed by the investigatory to be dose-limiting, such as: any toxicity that is possibly related to the study medication that requires the withdrawal of the participant from the study during 28-day DLT observation period), persistent Grade \>2 toxicities causing a delay of LY3475070 study treatment \>14 days during the 28-day DLT observation period.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

52 participants

Primary outcome timeframe

Up to 28 days from the first dose

Results posted on

2024-04-05

Participant Flow

The study was initially designed to be conducted in two phases: Phase 1a (dose escalation cohorts A, B) and Phase 1b (dose expansion cohorts C1, C2, D1, D2, E). Based on Sponsor decision, Phase 1b expansion cohorts were not initiated, no participants were enrolled.

Participant milestones

Participant milestones
Measure	Cohort A - 150mg QD LY3475070 Participants received 150 milligrams (mg) LY3475070 orally once daily (QD) on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 300mg QD LY3475070 Participants received 300mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 300mg BID LY3475070 Participants received 300mg LY3475070 orally twice daily (BID) on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 600mg QD LY3475070 Participants received 600mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 150mg QD LY3475070 + Pembrolizumab Participants received 150mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 150mg BID LY3475070 + Pembrolizumab Participants received 150mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 300mg QD LY3475070 + Pembrolizumab Participants received 300mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 300mg BID LY3475070 + Pembrolizumab Participants received 300mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study
Overall Study STARTED	4	6	6	4	3	11	1	17
Overall Study Received at Least 1 Dose of Study Drug	4	6	6	4	3	11	1	17
Overall Study COMPLETED	4	6	5	3	3	8	0	17
Overall Study NOT COMPLETED	0	0	1	1	0	3	1	0

Reasons for withdrawal

Reasons for withdrawal
Measure	Cohort A - 150mg QD LY3475070 Participants received 150 milligrams (mg) LY3475070 orally once daily (QD) on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 300mg QD LY3475070 Participants received 300mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 300mg BID LY3475070 Participants received 300mg LY3475070 orally twice daily (BID) on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 600mg QD LY3475070 Participants received 600mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 150mg QD LY3475070 + Pembrolizumab Participants received 150mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 150mg BID LY3475070 + Pembrolizumab Participants received 150mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 300mg QD LY3475070 + Pembrolizumab Participants received 300mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 300mg BID LY3475070 + Pembrolizumab Participants received 300mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study
Overall Study Withdrawal by Subject	0	0	0	1	0	1	1	0
Overall Study Lost to Follow-up	0	0	1	0	0	2	0	0

Baseline Characteristics

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Cohort A - 150mg QD LY3475070 n=4 Participants Participants received 150 milligrams (mg) LY3475070 orally once daily (QD) on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 300mg QD LY3475070 n=6 Participants Participants received 300mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 300mg BID LY3475070 n=6 Participants Participants received 300mg LY3475070 orally twice daily (BID) on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 600mg QD LY3475070 n=4 Participants Participants received 600mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 150mg QD LY3475070 + Pembrolizumab n=3 Participants Participants received 150mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 150mg BID LY3475070 + Pembrolizumab n=11 Participants Participants received 150mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 300mg QD LY3475070 + Pembrolizumab n=1 Participants Participants received 300mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 300mg BID LY3475070 + Pembrolizumab n=17 Participants Participants received 300mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study	Total n=52 Participants Total of all reporting groups
Age, Continuous	66.50 years STANDARD_DEVIATION 9.57 • n=5 Participants	65.83 years STANDARD_DEVIATION 13.04 • n=7 Participants	66.83 years STANDARD_DEVIATION 12.22 • n=5 Participants	66.25 years STANDARD_DEVIATION 13.02 • n=4 Participants	63.67 years STANDARD_DEVIATION 7.23 • n=21 Participants	59.73 years STANDARD_DEVIATION 11.65 • n=8 Participants	61 years STANDARD_DEVIATION 0 • n=8 Participants	66 years STANDARD_DEVIATION 7.66 • n=24 Participants	64.58 years STANDARD_DEVIATION 10.05 • n=42 Participants
Sex: Female, Male Female	2 Participants n=5 Participants	3 Participants n=7 Participants	2 Participants n=5 Participants	1 Participants n=4 Participants	1 Participants n=21 Participants	5 Participants n=8 Participants	1 Participants n=8 Participants	2 Participants n=24 Participants	17 Participants n=42 Participants
Sex: Female, Male Male	2 Participants n=5 Participants	3 Participants n=7 Participants	4 Participants n=5 Participants	3 Participants n=4 Participants	2 Participants n=21 Participants	6 Participants n=8 Participants	0 Participants n=8 Participants	15 Participants n=24 Participants	35 Participants n=42 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	3 Participants n=24 Participants	3 Participants n=42 Participants
Race (NIH/OMB) White	4 Participants n=5 Participants	6 Participants n=7 Participants	6 Participants n=5 Participants	4 Participants n=4 Participants	3 Participants n=21 Participants	11 Participants n=8 Participants	1 Participants n=8 Participants	14 Participants n=24 Participants	49 Participants n=42 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants
Region of Enrollment United States	2 Participants n=5 Participants	3 Participants n=7 Participants	6 Participants n=5 Participants	3 Participants n=4 Participants	2 Participants n=21 Participants	8 Participants n=8 Participants	1 Participants n=8 Participants	13 Participants n=24 Participants	38 Participants n=42 Participants
Region of Enrollment United Kingdom	2 Participants n=5 Participants	3 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	1 Participants n=21 Participants	3 Participants n=8 Participants	0 Participants n=8 Participants	4 Participants n=24 Participants	14 Participants n=42 Participants

PRIMARY outcome

Timeframe: Up to 28 days from the first dose

Population: All participants enrolled in the phase 1a who either completed 28 days of follow-up and at least 75% of LY3475070 treatment doses or discontinued treatment prior to 28 days due to a DLT.

Outcome measures

Outcome measures
Measure	Cohort A - 150mg QD LY3475070 n=4 Participants Participants received 150mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 300mg QD LY3475070 n=6 Participants Participants received 300mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 300mg BID LY3475070 n=6 Participants Participants received 300mg LY3475070 orally twice daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 600mg QD LY3475070 n=4 Participants Participants received 600mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 150mg QD LY3475070 + Pembrolizumab n=3 Participants Participants received 150mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 150mg BID LY3475070 + Pembrolizumab n=11 Participants Participants received 150mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 300mg QD LY3475070 + Pembrolizumab n=1 Participants Participants received 300mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 300mg BID LY3475070 + Pembrolizumab n=17 Participants Participants received 300mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study
Number of Participants With Dose Limiting Toxicities (DLTs)	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants	1 Participants

SECONDARY outcome

Timeframe: Cycle 1 Day 1 (Pre-dose, 0.5, 1, 2, 4, 6, 8 hours post-dose)

Population: All enrolled participants in phase1a who received LY3475070 and had intensively sampled evaluable PK data on cycle 1 day 1.

PK: AUC\[0-8\] of LY3475070.

Outcome measures

Outcome measures
Measure	Cohort A - 150mg QD LY3475070 n=4 Participants Participants received 150mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 300mg QD LY3475070 n=6 Participants Participants received 300mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 300mg BID LY3475070 n=5 Participants Participants received 300mg LY3475070 orally twice daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 600mg QD LY3475070 n=4 Participants Participants received 600mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 150mg QD LY3475070 + Pembrolizumab n=3 Participants Participants received 150mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 150mg BID LY3475070 + Pembrolizumab n=7 Participants Participants received 150mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 300mg QD LY3475070 + Pembrolizumab n=1 Participants Participants received 300mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 300mg BID LY3475070 + Pembrolizumab n=13 Participants Participants received 300mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Eight Hours (AUC[0-8]) of LY3475070	5880 nanogramshours per milliliter (ngh/mL) Geometric Coefficient of Variation 38.7	6580 nanogramshours per milliliter (ngh/mL) Geometric Coefficient of Variation 83.2	10700 nanogramshours per milliliter (ngh/mL) Geometric Coefficient of Variation 93.3	16000 nanogramshours per milliliter (ngh/mL) Geometric Coefficient of Variation 43.9	2990 nanogramshours per milliliter (ngh/mL) Geometric Coefficient of Variation 57.4	3680 nanogramshours per milliliter (ngh/mL) Geometric Coefficient of Variation 65.8	NA nanogramshours per milliliter (ngh/mL) Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation couldn't be calculated as there was only one participant. Individual value reported: 12600 ng\*h/mL	8960 nanogramshours per milliliter (ngh/mL) Geometric Coefficient of Variation 43.4

SECONDARY outcome

Timeframe: Cycle 2 Day 1 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 24 hours post-dose for the QD arms, Pre-dose, 0.5, 1, 2, 4, 6, 8 hours post-dose for the BID arms)

Population: All enrolled participants in phase1a who received LY3475070 and had intensively sampled evaluable PK data on cycle 2 day 1. For "Cohort B - 300mg QD LY3475070 + pembrolizumab," the participant has not received the treatment on cycle 2 day 1, and did not meet the analysis criteria. Thus, zero participants were analysed.

PK: AUCtau of LY3475070

Outcome measures

Outcome measures
Measure	Cohort A - 150mg QD LY3475070 n=4 Participants Participants received 150mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 300mg QD LY3475070 n=6 Participants Participants received 300mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 300mg BID LY3475070 n=3 Participants Participants received 300mg LY3475070 orally twice daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 600mg QD LY3475070 n=3 Participants Participants received 600mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 150mg QD LY3475070 + Pembrolizumab n=3 Participants Participants received 150mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 150mg BID LY3475070 + Pembrolizumab n=6 Participants Participants received 150mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 300mg QD LY3475070 + Pembrolizumab Participants received 300mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 300mg BID LY3475070 + Pembrolizumab n=12 Participants Participants received 300mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study
PK: Area Under the Concentration Versus Time Curve During 1 Dosing Interval (AUCtau) of LY3475070	7950 ng*h/mL Geometric Coefficient of Variation 73.6	8320 ng*h/mL Geometric Coefficient of Variation 106	19600 ng*h/mL Geometric Coefficient of Variation 117	26200 ng*h/mL Geometric Coefficient of Variation 11.4	3180 ng*h/mL Geometric Coefficient of Variation 152	3280 ng*h/mL Geometric Coefficient of Variation 370	—	12400 ng*h/mL Geometric Coefficient of Variation 80.2

SECONDARY outcome

Timeframe: Day 1 of Cycles 1 and 2 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 24 hours post-dose for the QD arms; Pre-dose, 0.5, 1, 2, 4, 6, 8 hours post-dose for the BID arms)

Population: All enrolled participants in phase1a who received LY3475070 and had intensively sampled evaluable PK data on cycle 1 day 1, cycle 2 day 1 for this outcome. For "Cohort B - 300mg QD LY3475070 + pembrolizumab," the participant has not received the treatment on cycle 2 day 1, and did not meet the analysis criteria. Thus, zero participants were analysed.

PK: Cmax of LY3475070

Outcome measures

Outcome measures
Measure	Cohort A - 150mg QD LY3475070 n=4 Participants Participants received 150mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 300mg QD LY3475070 n=6 Participants Participants received 300mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 300mg BID LY3475070 n=5 Participants Participants received 300mg LY3475070 orally twice daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 600mg QD LY3475070 n=4 Participants Participants received 600mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 150mg QD LY3475070 + Pembrolizumab n=3 Participants Participants received 150mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 150mg BID LY3475070 + Pembrolizumab n=8 Participants Participants received 150mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 300mg QD LY3475070 + Pembrolizumab n=1 Participants Participants received 300mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 300mg BID LY3475070 + Pembrolizumab n=15 Participants Participants received 300mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study
PK: Maximum Concentration (Cmax) of LY3475070 Cycle 1 Day 1	1750 ng/mL Geometric Coefficient of Variation 13.2	2060 ng/mL Geometric Coefficient of Variation 61.3	2960 ng/mL Geometric Coefficient of Variation 113	4320 ng/mL Geometric Coefficient of Variation 29.2	1100 ng/mL Geometric Coefficient of Variation 63.1	974 ng/mL Geometric Coefficient of Variation 107	NA ng/mL Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation couldn't be calculated as there was only one participant. Individual value reported: 3270 ng/mL	2670 ng/mL Geometric Coefficient of Variation 39.6
PK: Maximum Concentration (Cmax) of LY3475070 Cycle 2 Day 1	1770 ng/mL Geometric Coefficient of Variation 32.9	2310 ng/mL Geometric Coefficient of Variation 105	4270 ng/mL Geometric Coefficient of Variation 87.5	4610 ng/mL Geometric Coefficient of Variation 17.2	1340 ng/mL Geometric Coefficient of Variation 72.2	1060 ng/mL Geometric Coefficient of Variation 170	—	3200 ng/mL Geometric Coefficient of Variation 58.2

SECONDARY outcome

Timeframe: Baseline through Disease Progression or Death (Estimated at up to 10.4 Months)

Population: All enrolled participants in phase1a who received at least one dose of LY3475070.

ORR is the best overall tumor response of complete response (CR) or partial response (PR) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions.

Outcome measures

Outcome measures
Measure	Cohort A - 150mg QD LY3475070 n=4 Participants Participants received 150mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 300mg QD LY3475070 n=6 Participants Participants received 300mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 300mg BID LY3475070 n=6 Participants Participants received 300mg LY3475070 orally twice daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 600mg QD LY3475070 n=4 Participants Participants received 600mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 150mg QD LY3475070 + Pembrolizumab n=3 Participants Participants received 150mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 150mg BID LY3475070 + Pembrolizumab n=11 Participants Participants received 150mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 300mg QD LY3475070 + Pembrolizumab n=1 Participants Participants received 300mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 300mg BID LY3475070 + Pembrolizumab n=17 Participants Participants received 300mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study
Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR)	0 Percentage of participants	0 Percentage of participants	0 Percentage of participants	0 Percentage of participants	0 Percentage of participants	0 Percentage of participants	0 Percentage of participants	0 Percentage of participants

SECONDARY outcome

Timeframe: Baseline through Measured Progressive Disease (Estimated at up to 10.4 Months)

Population: All enrolled participants in phase1a who received at least one dose of LY3475070.

DCR is the percentage of participants with a best overall response of CR, PR or SD as defined by RECIST v1.1. CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

Outcome measures

Outcome measures
Measure	Cohort A - 150mg QD LY3475070 n=4 Participants Participants received 150mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 300mg QD LY3475070 n=6 Participants Participants received 300mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 300mg BID LY3475070 n=6 Participants Participants received 300mg LY3475070 orally twice daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 600mg QD LY3475070 n=4 Participants Participants received 600mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 150mg QD LY3475070 + Pembrolizumab n=3 Participants Participants received 150mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 150mg BID LY3475070 + Pembrolizumab n=11 Participants Participants received 150mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 300mg QD LY3475070 + Pembrolizumab n=1 Participants Participants received 300mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 300mg BID LY3475070 + Pembrolizumab n=17 Participants Participants received 300mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study
Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of CR, PR, and Stable Disease (SD)	50 Percentage of participants	33.3 Percentage of participants	16.7 Percentage of participants	0 Percentage of participants	66.7 Percentage of participants	27.3 Percentage of participants	0 Percentage of participants	35.3 Percentage of participants

SECONDARY outcome

Timeframe: Baseline to Objective Progression or Death Due to Any Cause (Estimated at up to 10.4 Months)

Population: All enrolled participants in phase1a who received at least one dose of LY3475070 (including censored). Number of participants censored: 150mg QD LY3475070=1, 300mg QD LY3475070=1, 300mg BID LY3475070=4, 600mg QD LY3475070=1, 150mg QD LY3475070 + pembrolizumab=2, 150mg BID LY3475070 + pembrolizumab=5, 300mg QD LY3475070 + pembrolizumab=1, 300mg BID LY3475070 + pembrolizumab=14.

PFS is defined as the time from the date of start of treatment to the first date of the observed clinical or radiologically documented progressive disease or death due to any cause, whichever occurs first, was estimated and reported for all evaluable participants. For participants who were not known to have died or progressed as of the data-inclusion cut-off date, PFS time was censored at the date of the last objective progression-free disease assessment prior to the date of any subsequent systematic anticancer therapy.

Outcome measures

Outcome measures
Measure	Cohort A - 150mg QD LY3475070 n=4 Participants Participants received 150mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 300mg QD LY3475070 n=6 Participants Participants received 300mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 300mg BID LY3475070 n=6 Participants Participants received 300mg LY3475070 orally twice daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 600mg QD LY3475070 n=4 Participants Participants received 600mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 150mg QD LY3475070 + Pembrolizumab n=3 Participants Participants received 150mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 150mg BID LY3475070 + Pembrolizumab n=11 Participants Participants received 150mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 300mg QD LY3475070 + Pembrolizumab n=1 Participants Participants received 300mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 300mg BID LY3475070 + Pembrolizumab n=17 Participants Participants received 300mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study
Progression-Free Survival (PFS)	2.71 Months Interval 0.03 to 3.42	1.91 Months Interval 0.03 to 4.8	0.89 Months Interval 0.03 to 2.14	1.33 Months Interval 0.03 to 2.04	2 Months Interval 0.03 to 2.04	0.53 Months Interval 0.03 to 3.52	0.03 Months Interval 0.03 to 0.03	0.03 Months Interval 0.03 to 2.5

Adverse Events

Cohort A - 150mg QD LY3475070

Serious events: 0 serious events

Other events: 4 other events

Deaths: 4 deaths

Cohort A - 300mg QD LY3475070

Serious events: 0 serious events

Other events: 6 other events

Deaths: 5 deaths

Cohort A - 300mg BID LY3475070

Serious events: 0 serious events

Other events: 6 other events

Deaths: 1 deaths

Cohort A - 600mg QD LY3475070

Serious events: 2 serious events

Other events: 4 other events

Deaths: 2 deaths

Cohort B - 150mg QD LY3475070 + Pembrolizumab

Serious events: 1 serious events

Other events: 2 other events

Deaths: 1 deaths

Cohort B - 150mg BID LY3475070 + Pembrolizumab

Serious events: 3 serious events

Other events: 11 other events

Deaths: 3 deaths

Cohort B - 300mg QD LY3475070 + Pembrolizumab

Serious events: 1 serious events

Other events: 1 other events

Deaths: 0 deaths

Cohort B - 300mg BID LY3475070 + Pembrolizumab

Serious events: 7 serious events

Other events: 16 other events

Deaths: 3 deaths

Serious adverse events

Serious adverse events
Measure	Cohort A - 150mg QD LY3475070 n=4 participants at risk Participants received 150 milligrams (mg) LY3475070 orally once daily (QD) on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 300mg QD LY3475070 n=6 participants at risk Participants received 300mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 300mg BID LY3475070 n=6 participants at risk Participants received 300mg LY3475070 orally twice daily (BID) on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 600mg QD LY3475070 n=4 participants at risk Participants received 600mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 150mg QD LY3475070 + Pembrolizumab n=3 participants at risk Participants received 150mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 150mg BID LY3475070 + Pembrolizumab n=11 participants at risk Participants received 150mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 300mg QD LY3475070 + Pembrolizumab n=1 participants at risk Participants received 300mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 300mg BID LY3475070 + Pembrolizumab n=17 participants at risk Participants received 300mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Cardiac disorders Myocardial infarction	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	100.0% 1/1 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Cardiac disorders Supraventricular tachycardia	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Endocrine disorders Adrenal insufficiency	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Nausea	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Vomiting	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
General disorders Fatigue	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
General disorders Pyrexia	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Hepatobiliary disorders Liver injury	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Infections and infestations Covid-19	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	25.0% 1/4 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Infections and infestations Pneumonia	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Infections and infestations Sepsis	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Infections and infestations Urinary tract infection	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 1/3 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Investigations Alanine aminotransferase increased	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	100.0% 1/1 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Investigations Aspartate aminotransferase increased	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	100.0% 1/1 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Nervous system disorders Dizziness	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Nervous system disorders Immune-mediated encephalitis	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Psychiatric disorders Confusional state	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Renal and urinary disorders Immune-mediated nephritis	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	25.0% 1/4 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	25.0% 1/4 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Skin and subcutaneous tissue disorders Dermatitis bullous	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

Other adverse events

Other adverse events
Measure	Cohort A - 150mg QD LY3475070 n=4 participants at risk Participants received 150 milligrams (mg) LY3475070 orally once daily (QD) on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 300mg QD LY3475070 n=6 participants at risk Participants received 300mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 300mg BID LY3475070 n=6 participants at risk Participants received 300mg LY3475070 orally twice daily (BID) on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort A - 600mg QD LY3475070 n=4 participants at risk Participants received 600mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 150mg QD LY3475070 + Pembrolizumab n=3 participants at risk Participants received 150mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 150mg BID LY3475070 + Pembrolizumab n=11 participants at risk Participants received 150mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 300mg QD LY3475070 + Pembrolizumab n=1 participants at risk Participants received 300mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.	Cohort B - 300mg BID LY3475070 + Pembrolizumab n=17 participants at risk Participants received 300mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	25.0% 1/4 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	100.0% 1/1 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Nervous system disorders Headache	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 2/6 • Number of events 7 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 1/3 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	27.3% 3/11 • Number of events 3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	11.8% 2/17 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Nervous system disorders Hemiparesis	25.0% 1/4 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Nervous system disorders Hypoaesthesia	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Nervous system disorders Neuropathy peripheral	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Nervous system disorders Paraesthesia	25.0% 1/4 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Nervous system disorders Peripheral sensory neuropathy	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Nervous system disorders Presyncope	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Nervous system disorders Spinal cord compression	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 1/3 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Psychiatric disorders Anxiety	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Psychiatric disorders Confusional state	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Psychiatric disorders Insomnia	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	11.8% 2/17 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Psychiatric disorders Mental status changes	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Psychiatric disorders Psychotic disorder	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	100.0% 1/1 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Psychiatric disorders Sleep disorder	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Renal and urinary disorders Bladder pain	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Renal and urinary disorders Dysuria	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Renal and urinary disorders Haematuria	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Renal and urinary disorders Hydroureter	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Renal and urinary disorders Micturition urgency	25.0% 1/4 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Renal and urinary disorders Urinary hesitation	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Renal and urinary disorders Urinary incontinence	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Renal and urinary disorders Urinary retention	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Reproductive system and breast disorders Vaginal haemorrhage	0.00% 0/2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	50.0% 1/2 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/5 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Respiratory, thoracic and mediastinal disorders Dysphonia	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	50.0% 3/6 • Number of events 5 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	25.0% 1/4 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	100.0% 1/1 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	17.6% 3/17 • Number of events 3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Respiratory, thoracic and mediastinal disorders Hiccups	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	25.0% 1/4 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	25.0% 1/4 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	25.0% 1/4 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 1/3 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Respiratory, thoracic and mediastinal disorders Upper-airway cough syndrome	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 1/3 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Respiratory, thoracic and mediastinal disorders Wheezing	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Skin and subcutaneous tissue disorders Dermatitis acneiform	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Skin and subcutaneous tissue disorders Erythema	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 2/6 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Skin and subcutaneous tissue disorders Hyperhidrosis	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Skin and subcutaneous tissue disorders Psoriasis	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 1/3 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Skin and subcutaneous tissue disorders Rash	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	25.0% 1/4 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 1/3 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	11.8% 2/17 • Number of events 6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Blood and lymphatic system disorders Anaemia	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 2/6 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	41.2% 7/17 • Number of events 11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Skin and subcutaneous tissue disorders Rash macular	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Cardiac disorders Atrial fibrillation	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 2/6 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Cardiac disorders Palpitations	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Cardiac disorders Sinus tachycardia	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Endocrine disorders Hyperthyroidism	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Endocrine disorders Hypothyroidism	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Eye disorders Eye irritation	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Eye disorders Eye pain	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Abdominal discomfort	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Abdominal distension	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	25.0% 1/4 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Abdominal pain	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	23.5% 4/17 • Number of events 4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Abdominal rigidity	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Constipation	25.0% 1/4 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	25.0% 1/4 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 1/3 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	18.2% 2/11 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	17.6% 3/17 • Number of events 3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Diarrhoea	25.0% 1/4 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 2/6 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	50.0% 2/4 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	18.2% 2/11 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	41.2% 7/17 • Number of events 7 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Dry mouth	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 1/3 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Dyspepsia	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	25.0% 1/4 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Dysphagia	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 2/6 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Nausea	50.0% 2/4 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	50.0% 2/4 • Number of events 3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	27.3% 3/11 • Number of events 4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	100.0% 1/1 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	47.1% 8/17 • Number of events 10 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Oral pain	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Paraesthesia oral	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Stomatitis	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Gastrointestinal disorders Vomiting	25.0% 1/4 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	25.0% 1/4 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	18.2% 2/11 • Number of events 3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	23.5% 4/17 • Number of events 8 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
General disorders Chest pain	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	25.0% 1/4 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
General disorders Chills	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	100.0% 1/1 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	17.6% 3/17 • Number of events 3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
General disorders Fatigue	50.0% 2/4 • Number of events 3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 2/6 • Number of events 3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	50.0% 3/6 • Number of events 3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	50.0% 2/4 • Number of events 5 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	36.4% 4/11 • Number of events 4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	100.0% 1/1 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	29.4% 5/17 • Number of events 10 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
General disorders Hypothermia	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
General disorders Influenza like illness	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
General disorders Localised oedema	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
General disorders Malaise	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
General disorders Mucosal inflammation	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
General disorders Oedema peripheral	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 2/6 • Number of events 4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
General disorders Pain	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
General disorders Polyp	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Nervous system disorders Cerebrovascular accident	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
General disorders Pyrexia	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	17.6% 3/17 • Number of events 4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Hepatobiliary disorders Cholangitis acute	25.0% 1/4 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Immune system disorders Seasonal allergy	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Infections and infestations Breast cellulitis	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Infections and infestations Cellulitis	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Infections and infestations Covid-19	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	100.0% 1/1 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Infections and infestations Pneumonia	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	25.0% 1/4 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	18.2% 2/11 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Infections and infestations Rash pustular	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Infections and infestations Sepsis	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Infections and infestations Sinusitis	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	100.0% 1/1 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Infections and infestations Skin infection	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Infections and infestations Upper respiratory tract infection	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	11.8% 2/17 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Infections and infestations Urinary tract infection	25.0% 1/4 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 1/3 • Number of events 3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	17.6% 3/17 • Number of events 4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Injury, poisoning and procedural complications Fall	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Injury, poisoning and procedural complications Rib fracture	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Injury, poisoning and procedural complications Subdural haematoma	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Investigations Alanine aminotransferase increased	50.0% 2/4 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	50.0% 3/6 • Number of events 4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	17.6% 3/17 • Number of events 4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Investigations Amylase increased	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Investigations Aspartate aminotransferase increased	50.0% 2/4 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 2/6 • Number of events 3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	18.2% 2/11 • Number of events 3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	11.8% 2/17 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Investigations Blood alkaline phosphatase increased	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Investigations Blood bilirubin increased	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Investigations Blood creatinine increased	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 2/6 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	11.8% 2/17 • Number of events 6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Investigations Blood potassium decreased	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	50.0% 2/4 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Investigations Lipase increased	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Investigations Lymphocyte count decreased	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Investigations Platelet count decreased	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	11.8% 2/17 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Investigations Weight decreased	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Investigations White blood cell count increased	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Metabolism and nutrition disorders Decreased appetite	25.0% 1/4 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 2/6 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	25.0% 1/4 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 1/3 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	18.2% 2/11 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	17.6% 3/17 • Number of events 4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Metabolism and nutrition disorders Dehydration	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	11.8% 2/17 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	11.8% 2/17 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Metabolism and nutrition disorders Hypokalaemia	25.0% 1/4 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	11.8% 2/17 • Number of events 3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Metabolism and nutrition disorders Hypomagnesaemia	25.0% 1/4 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	11.8% 2/17 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 2/6 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 1/3 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	23.5% 4/17 • Number of events 5 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Musculoskeletal and connective tissue disorders Back pain	25.0% 1/4 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 2/6 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	25.0% 1/4 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	18.2% 2/11 • Number of events 4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Musculoskeletal and connective tissue disorders Bone pain	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Musculoskeletal and connective tissue disorders Flank pain	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Musculoskeletal and connective tissue disorders Groin pain	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Musculoskeletal and connective tissue disorders Joint swelling	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Musculoskeletal and connective tissue disorders Osteonecrosis	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	11.8% 2/17 • Number of events 5 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to central nervous system	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	11.8% 2/17 • Number of events 6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Nervous system disorders Dizziness	25.0% 1/4 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	33.3% 2/6 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	18.2% 2/11 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Skin and subcutaneous tissue disorders Skin lesion	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Social circumstances Tanning	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Vascular disorders Deep vein thrombosis	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Vascular disorders Hot flush	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Vascular disorders Hypertension	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	9.1% 1/11 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Vascular disorders Hypotension	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	16.7% 1/6 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	11.8% 2/17 • Number of events 2 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Vascular disorders Peripheral artery occlusion	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	5.9% 1/17 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
Vascular disorders Thrombosis	25.0% 1/4 • Number of events 1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/6 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/4 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/3 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/11 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/1 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.	0.00% 0/17 • Baseline up to 10.4 months All enrolled participants in phase1a who received at least one dose of LY3475070. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

Additional Information

Chief Medical Officer

Eli Lilly and Company

Phone: 800-545-5979

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Restriction type: GT60